Ah Equity Partners Bio Ii, L.L.C. Erasca, Inc. Transaction History
Ah Equity Partners Bio Ii, L.L.C.
- $144 Million
- Q3 2022
A detailed history of Ah Equity Partners Bio Ii, L.L.C. transactions in Erasca, Inc. stock. As of the latest transaction made, Ah Equity Partners Bio Ii, L.L.C. holds 2,500,000 shares of ERAS stock, worth $5.8 Million. This represents 13.59% of its overall portfolio holdings.
Number of Shares
2,500,000
Previous 2,500,000
-0.0%
Holding current value
$5.8 Million
Previous $13.9 Million
40.04%
% of portfolio
13.59%
Previous 9.78%
Shares
1 transactions
Others Institutions Holding ERAS
# of Institutions
117Shares Held
74.3MCall Options Held
7.1KPut Options Held
40.1K-
Arch Venture Management, LLC Chicago, IL11.1MShares$25.6 Million33.14% of portfolio
-
Black Rock Inc. New York, NY6.98MShares$16.2 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY6.17MShares$14.3 Million0.17% of portfolio
-
Artal Group S.A. Luxembourg, N44.72MShares$11 Million0.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.34MShares$10.1 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $283M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...